Prognostic Impact of TERT Promoter Mutations in Adult-Type Diffuse Gliomas Based on WHO2021 Criteria

Yujin Lee,Chul-Kee Park,Sung-Hye Park
DOI: https://doi.org/10.3390/cancers16112032
2024-05-28
Cancers
Abstract:Mutation in the telomerase reverse transcriptase promoter (TERTp )is commonly observed in various malignancies, such as central nervous system (CNS) tumors, malignant melanoma, bladder cancer, and thyroid carcinoma. These mutations are recognized as significant poor prognostic factors for these tumors. In this investigation, a total of 528 cases of adult-type diffuse gliomas diagnosed at a single institution were reclassified according to the 2021 WHO classifications of CNS tumors, 5th edition (WHO2021). The study analyzed clinicopathological and genetic features, including TERTp mutations in each tumor. The impact of known prognostic factors on patient outcomes was analyzed through Kaplan–Meier survival and Cox regression analysis. TERTp mutations were predominantly identified in 94.1% of oligodendrogliomas (ODG), followed by 66.3% in glioblastoma, IDH-wildtype (GBM-IDHwt), and 9.2% of astrocytomas, IDH-mutant (A-IDHm). When considering A-IDHm and GBM as astrocytic tumors (Group 1) and ODGs (Group 2), TERTp mutations emerged as a significant adverse prognostic factor (p = 0.013) in Group 1. However, within each GBM-IDHwt and A-IDHm, the presence of TERTp mutations did not significantly impact patient prognosis (p = 0.215 and 0.268, respectively). Due to the high frequency of TERTp mutations in Group 2 (ODG) and their consistent prolonged survival, a statistical analysis to evaluate their impact on overall survival was deemed impractical. When considering MGMTp status, the combined TERTp-mutated and MGMTp-unmethylated group exhibited the worst prognosis in OS (p = 0.018) and PFS (p = 0.034) of GBM. This study confirmed that the classification of tumors according to the WHO2021 criteria effectively reflected prognosis. Both uni- and multivariate analyses in GBM, age, MGMTp methylation, and CDKN2A/B homozygous deletion were statistically significant prognostic factors while in univariate analysis in A-IDHm, grade 4, the Ki-67 index and MYCN amplifications were statistically significant prognostic factors. This study suggests that it is important to classify and manage tumors based on their genetic characteristics in adult-type diffuse gliomas.
oncology
What problem does this paper attempt to address?
### Problems the Paper Attempts to Solve This paper aims to explore the prognostic impact of telomerase reverse transcriptase promoter (TERTp) mutations in adult diffuse gliomas reclassified according to the 2021 World Health Organization (WHO) classification criteria. Specifically, the researchers seek to evaluate the prognostic significance of TERTp mutations in different subgroups by analyzing the clinicopathological and genetic characteristics of 528 adult diffuse glioma cases. ### Main Research Content 1. **Background Introduction**: - Telomerase reverse transcriptase promoter (TERTp) mutations are common in various malignancies, particularly in central nervous system (CNS) tumors. - These mutations are considered adverse prognostic factors for these tumors. - The 2021 WHO classification criteria for CNS tumors have been updated, emphasizing the importance of molecular genetic markers in diagnosis and prognostic evaluation. 2. **Research Objectives**: - To evaluate the prognostic impact of TERTp mutations in adult diffuse gliomas. - To investigate the impact of other known prognostic factors (such as age, MGMT promoter methylation, CDKN2A/B homozygous deletion, etc.) on patient prognosis. 3. **Research Methods**: - **Patient Selection**: 528 adult diffuse glioma patients were selected from the archives of Seoul National University Hospital from 2005 to 2022. - **Immunohistochemistry**: Immunohistochemical staining was performed using various antibodies, including p53, Olig2, Ki-67, ATRX, IDH1 R132H mutation, and H3 K27M. - **DNA and RNA Extraction**: DNA and RNA were extracted from paraffin-embedded tissue sections. - **Fluorescence In Situ Hybridization (FISH)**: Used to detect 1p and 19q deletions. - **Sanger Sequencing**: Used to detect IDH1/IDH2 mutations. - **TERT Promoter Mutation Analysis**: TERTp hotspot mutations C228T and C250T were detected by PCR amplification and Sanger sequencing. - **Methylation-Specific PCR**: Used to detect the methylation status of the MGMT promoter. - **Next-Generation Sequencing (NGS)**: Sequencing was performed using a custom brain tumor gene panel. 4. **Results**: - **TERTp Mutation Frequency**: In GBM-IDHwt, the TERTp mutation rate was 66.3%, with C228T mutations accounting for 73.8% and C250T mutations accounting for 26.2%. In A-IDHm, the TERTp mutation rate was lower, at 7.0% (G3) and 14.3% (G4). In ODG, the TERTp mutation rate was as high as 94.1%. - **Prognostic Impact**: TERTp mutations were a significant adverse prognostic factor in GBM-IDHwt and A-IDHm (collectively referred to as Group 1) (p<0.001). However, in ODG (referred to as Group 2), TERTp mutation status had no significant impact on overall survival (OS) and progression-free survival (PFS). - **Combined Analysis of MGMT Promoter Methylation and TERTp Mutations**: In GBM-IDHwt patients, those with both TERTp mutations and unmethylated MGMTp had the worst prognosis (p=0.018 for OS, p=0.034 for PFS). ### Conclusion This study confirms the validity of classifying adult diffuse gliomas according to the 2021 WHO classification criteria and emphasizes the importance of considering multiple molecular genetic features, not just TERTp mutation status, in prognostic evaluation. This provides an important reference for more precise diagnosis and personalized treatment strategies in the future.